FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096358103> ?p ?o ?g. }

• W3096358103 endingPage "13" @default.
• W3096358103 startingPage "12" @default.
• W3096358103 abstract "Background: Cytogenetic abnormalities detected by fluorescence in situ hybridization (FISH) are known to differentially impact prognosis in patients with chronic lymphocytic leukemia (CLL). Deletion6q23 (del6q23) has been reported in ~2-3% of CLL patients at diagnosis; however, its prognostic significance remains indeterminate. Methods: We identified previously untreated CLL patients from the Mayo Clinic CLL Database seen between 1/1995 - 2/2020 who had FISH performed. The clinical characteristics, concomitant cytogenetic abnormalities, time to first therapy (TTFT), and overall survival (OS) were compared between patients with del6q23 to those without this abnormality. TTFT was analyzed from FISH date until treatment or last known untreated date, accounting for competing risk of death. OS was analyzed using Kaplan-Meier methods from FISH date. In a matched (CLL-IPI risk score and sex) analysis, Cox regression analysis was used to determine the association between TTFT/OS and presence of del6q23. The Mayo Clinic IRB approved this study. Results: A total of 3101 CLL patients were identified; their median age at diagnosis was 64 years and 66% were male. Of these patients, 42 (1.3%) had evidence of del6q23 by FISH. Compared to patients without del6q23, patients with del6q23 carried a more adverse clinical and cytogenetic profile at the time of diagnosis including advanced Rai stage (22% Rai III/IV vs. 9% Rai III/IV; P = 0.002), unmutated IGHV genes (91% vs. 43%; P &lt; 0.001), and high/very high risk CLL-IPI (50% vs. 27%; P &lt; 0.001). Del6q23 was the sole abnormality in 13 patients (31%). Of the remaining patients, del6q23 was concomitantly present with del13q in 8 patients (19%), and with either del11q or del17p in 21 patients (50%). Of the 42 patients with del6q23, 29 received first line therapy: chemoimmunotherapy in 16 patients, BTK inhibitor in 7 patients, and an anti-CD20 monoclonal antibody alone in 6 patients. The median follow-up of the entire cohort was 7.3 years. The median TTFT in patients with del6q23 was 0.7 years while the 5-year OS was 76%. Patients with del6q23 demonstrated significantly shorter TTFT and reduced OS when compared to patients without del6q23 (Figures 1A and 1B). The shorter TTFT was also evident for patients with del6q23 compared to patients without del6q23 divided according to the Dohner risk category (Figure 2A), although there was no difference in OS between these groups of patients (Figure 2B). Because del6q23 patients were enriched for other unfavorable prognostic markers, we identified four control patients without del6q23, matched by CLL-IPI risk score and sex, to each treatment-naïve patient with del6q23. Patients with del6q23 showed a borderline statistically significant shorter TTFT (median 0.7 years versus 3.9 years; P = 0.07) and a nonsignificant association with OS (median 10.9 years versus 10.3 years; P = 0.28). Conclusion: Del6q23 by FISH in previously untreated CLL represents an uncommon abnormality. When compared to patients without del6q23, patients with del6q23 tend to have more adverse clinical and cytogenetic profiles at baseline, which likely confer a worse prognosis as reflected by shorter TTFT compared to patients without this abnormality. Figure Disclosures Ding: Merck: Membership on an entity's Board of Directors or advisory committees, Research Funding; DTRM: Research Funding; Beigene: Membership on an entity's Board of Directors or advisory committees; alexion: Membership on an entity's Board of Directors or advisory committees; MEI Pharma: Membership on an entity's Board of Directors or advisory committees; Octapharma: Membership on an entity's Board of Directors or advisory committees; Abbvie: Research Funding; Astra Zeneca: Research Funding. Wang:Novartis: Research Funding; Innocare: Research Funding; Incyte: Research Funding. Braggio:DASA: Consultancy; Bayer: Other: Stock Owner; Acerta Pharma: Research Funding. Kay:Sunesis: Research Funding; Abbvie: Research Funding; Tolero Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Meyer Squib: Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno Theraputics: Membership on an entity's Board of Directors or advisory committees; Dava Oncology: Membership on an entity's Board of Directors or advisory committees; Oncotracker: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Morpho-sys: Membership on an entity's Board of Directors or advisory committees; Cytomx: Membership on an entity's Board of Directors or advisory committees; Agios Pharma: Membership on an entity's Board of Directors or advisory committees; Acerta Pharma: Research Funding; MEI Pharma: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees. Kenderian:Juno: Research Funding; Gilead: Research Funding; Lentigen: Research Funding; MorphoSys: Research Funding; Sunesis: Research Funding; Kite: Research Funding; Novartis: Patents & Royalties, Research Funding; Torque: Consultancy; Humanigen: Consultancy, Patents & Royalties, Research Funding; Mettaforge: Patents & Royalties; Tolero: Research Funding; BMS: Research Funding. Parikh:Ascentage Pharma: Research Funding; Merck: Research Funding; AbbVie: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; TG Therapeutics: Research Funding; Pharmacyclics: Honoraria, Research Funding; GlaxoSmithKline: Honoraria; Janssen: Honoraria, Research Funding; MorphoSys: Research Funding; Genentech: Honoraria; Verastem Oncology: Honoraria." @default.
• W3096358103 created "2020-11-09" @default.
• W3096358103 creator A5002515721 @default.
• W3096358103 creator A5006201509 @default.
• W3096358103 creator A5008437556 @default.
• W3096358103 creator A5009747339 @default.
• W3096358103 creator A5029811322 @default.
• W3096358103 creator A5034734777 @default.
• W3096358103 creator A5038008601 @default.
• W3096358103 creator A5041356401 @default.
• W3096358103 creator A5045789519 @default.
• W3096358103 creator A5051752737 @default.
• W3096358103 creator A5054196868 @default.
• W3096358103 creator A5054300127 @default.
• W3096358103 creator A5060532068 @default.
• W3096358103 creator A5065900666 @default.
• W3096358103 creator A5067100969 @default.
• W3096358103 creator A5075005037 @default.
• W3096358103 creator A5077686486 @default.
• W3096358103 creator A5078869044 @default.
• W3096358103 creator A5082845313 @default.
• W3096358103 creator A5087950597 @default.
• W3096358103 date "2020-11-05" @default.
• W3096358103 modified "2023-10-03" @default.
• W3096358103 title "Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia" @default.
• W3096358103 doi "https://doi.org/10.1182/blood-2020-139068" @default.
• W3096358103 hasPublicationYear "2020" @default.
• W3096358103 type Work @default.
• W3096358103 sameAs 3096358103 @default.
• W3096358103 citedByCount "0" @default.
• W3096358103 crossrefType "journal-article" @default.
• W3096358103 hasAuthorship W3096358103A5002515721 @default.
• W3096358103 hasAuthorship W3096358103A5006201509 @default.
• W3096358103 hasAuthorship W3096358103A5008437556 @default.
• W3096358103 hasAuthorship W3096358103A5009747339 @default.
• W3096358103 hasAuthorship W3096358103A5029811322 @default.
• W3096358103 hasAuthorship W3096358103A5034734777 @default.
• W3096358103 hasAuthorship W3096358103A5038008601 @default.
• W3096358103 hasAuthorship W3096358103A5041356401 @default.
• W3096358103 hasAuthorship W3096358103A5045789519 @default.
• W3096358103 hasAuthorship W3096358103A5051752737 @default.
• W3096358103 hasAuthorship W3096358103A5054196868 @default.
• W3096358103 hasAuthorship W3096358103A5054300127 @default.
• W3096358103 hasAuthorship W3096358103A5060532068 @default.
• W3096358103 hasAuthorship W3096358103A5065900666 @default.
• W3096358103 hasAuthorship W3096358103A5067100969 @default.
• W3096358103 hasAuthorship W3096358103A5075005037 @default.
• W3096358103 hasAuthorship W3096358103A5077686486 @default.
• W3096358103 hasAuthorship W3096358103A5078869044 @default.
• W3096358103 hasAuthorship W3096358103A5082845313 @default.
• W3096358103 hasAuthorship W3096358103A5087950597 @default.
• W3096358103 hasBestOaLocation W30963581031 @default.
• W3096358103 hasConcept C104317684 @default.
• W3096358103 hasConcept C126322002 @default.
• W3096358103 hasConcept C146357865 @default.
• W3096358103 hasConcept C151730666 @default.
• W3096358103 hasConcept C2777542201 @default.
• W3096358103 hasConcept C2777609679 @default.
• W3096358103 hasConcept C2777938653 @default.
• W3096358103 hasConcept C2778461978 @default.
• W3096358103 hasConcept C2779384505 @default.
• W3096358103 hasConcept C30481170 @default.
• W3096358103 hasConcept C50382708 @default.
• W3096358103 hasConcept C55493867 @default.
• W3096358103 hasConcept C71924100 @default.
• W3096358103 hasConcept C86803240 @default.
• W3096358103 hasConcept C90924648 @default.
• W3096358103 hasConceptScore W3096358103C104317684 @default.
• W3096358103 hasConceptScore W3096358103C126322002 @default.
• W3096358103 hasConceptScore W3096358103C146357865 @default.
• W3096358103 hasConceptScore W3096358103C151730666 @default.
• W3096358103 hasConceptScore W3096358103C2777542201 @default.
• W3096358103 hasConceptScore W3096358103C2777609679 @default.
• W3096358103 hasConceptScore W3096358103C2777938653 @default.
• W3096358103 hasConceptScore W3096358103C2778461978 @default.
• W3096358103 hasConceptScore W3096358103C2779384505 @default.
• W3096358103 hasConceptScore W3096358103C30481170 @default.
• W3096358103 hasConceptScore W3096358103C50382708 @default.
• W3096358103 hasConceptScore W3096358103C55493867 @default.
• W3096358103 hasConceptScore W3096358103C71924100 @default.
• W3096358103 hasConceptScore W3096358103C86803240 @default.
• W3096358103 hasConceptScore W3096358103C90924648 @default.
• W3096358103 hasIssue "Supplement 1" @default.
• W3096358103 hasLocation W30963581031 @default.
• W3096358103 hasOpenAccess W3096358103 @default.
• W3096358103 hasPrimaryLocation W30963581031 @default.
• W3096358103 hasRelatedWork W2063710350 @default.
• W3096358103 hasRelatedWork W2080678136 @default.
• W3096358103 hasRelatedWork W2126386241 @default.
• W3096358103 hasRelatedWork W2589130651 @default.
• W3096358103 hasRelatedWork W2597315323 @default.
• W3096358103 hasRelatedWork W282401845 @default.
• W3096358103 hasRelatedWork W2979734186 @default.
• W3096358103 hasRelatedWork W3012744088 @default.
• W3096358103 hasRelatedWork W3115057018 @default.
• W3096358103 hasRelatedWork W4362506973 @default.
• W3096358103 hasVolume "136" @default.
• W3096358103 isParatext "false" @default.

• next